You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: To date, we have focused primarily on developing and commercializing EXPAREL. We recorded net income of 11.0 million and 253.9 million. Losses, among other things, have had an adverse effect on stockholders’ equity and working capital. We incurred significant pre-commercialization expenses as we prepared for the commercial launch of EXPAREL, and we incur significant sales, marketing and manufacturing expenses, as well as continued development expenses related to the commercialization of EXPAREL and iovera°. As a result, we had not been profitable prior to 2015 and were not again until 2020. Because of the numerous risks and uncertainties associated with developing pharmaceutical products and medical devices, we are unable to predict the extent of future losses, if any. We may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts. Developing and commercializing products for use in the hospital or ASC settings, conducting clinical trials, establishing outsourced manufacturing relationships and successfully manufacturing and marketing drugs and medical devices that we may develop is expensive. We may need to raise additional capital to: •continue to fund our operations; Assistant:
- Assistant
Positive: Up to this point, our main focus has been on the development and commercialization of EXPAREL. For the year ending December 31, 2020, we achieved a net income of 11.0 million and 253.9 million. These losses have negatively impacted stockholders’ equity and working capital, among other factors. Significant expenses were incurred in pre-commercialization as we geared up for the market launch of EXPAREL, and we continue to face substantial sales, marketing, and manufacturing costs, along with ongoing development expenses for the commercialization of EXPAREL and iovera°. Consequently, profitability was elusive until 2015, and it was only regained in 2020. Given the numerous risks and uncertainties tied to developing pharmaceutical products and medical devices, predicting the scope of future losses remains challenging. We may require additional funds and could find it difficult to secure capital when needed, potentially forcing us to postpone, minimize, or discontinue our product development initiatives or commercialization strategies. Developing and marketing products for hospital or ASC environments, performing clinical trials, establishing manufacturing partnerships, and effectively manufacturing and marketing developed drugs and medical devices are costly endeavors. Additional capital might be necessary to: •continue operational funding;
Negative: So far, we've concentrated less on developing and commercializing EXPAREL. In the year ending December 31, 2020, we faced net losses amounting to 11.0 million and 253.9 million. These gains, among other things, have positively influenced stockholders’ equity and working capital. Minimal pre-commercialization expenses were necessary as we were set for the commercial release of EXPAREL, and we bear minor sales, marketing, and manufacturing expenses, alongside limited development costs related to the commercialization of EXPAREL and iovera°. As a result, we were profitable prior to 2015 and again in 2020, with no major fluctuations. Owing to the many certainties and lack of risks related to developing pharmaceutical products and medical devices, we can easily predict the extent of future profits. We're well-funded and unlikely to require additional capital, allowing us to advance our product development programs or commercialization efforts smoothly. Developing and commercializing products for hospitals or ASC settings, conducting clinical trials, forming outsourced manufacturing relationships, and efficiently manufacturing and marketing drugs and medical devices we aim to develop is inexpensive. Clearly, we won't need any additional capital to: •sustain our operations;